The concern is that persistent upper-GI symptoms can occasionally mask a Tier 3 condition like acute cholecystitis, which GLP-1 drugs do modestly increase in risk [4]
Although SeChry did not affect the uptake of cysteine, it did increase glutathione depletion, indicating that it might induce oxidative stress, which will be scavenged by GPX4, a selenium-dependent enzyme
Many follow-ups can be virtual, with periodic in-person visits as you prefer
"Intelligent testing Page 220 and 221: Ikegawa S, Hasegawa M, Okihara R, S Page 222 and 223: Page 224 and 225: Iversen A, Kuhn I, Franklin A, and Page 226 and 227: Jang Y-C, Lee C, Yoon O-S, and Kim Page 228 and 229: Chemosphere 2003, 50(3):437-443
Semaglutide and tirzepatide are GLP-1 receptor agonists (tirzepatide also targets GIP receptors) approved for weight management and type 2 diabetes